ReN 003

Drug Profile

ReN 003

Alternative Names: hRPC therapy - ReNeuron; ReN003

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard Medical School; ReNeuron; Schepens Eye Research Institute
  • Developer ReNeuron
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa

Most Recent Events

  • 11 Jul 2018 ReNeuron signs an exclusivity agreement with a US-based specialty pharmaceutical company to out-license hRPC retinal stem cell technology and therapeutic programmes
  • 26 Mar 2018 ReNeuron announces intention to submit clinical trial application for Cone-rod dystrophy
  • 14 Dec 2017 ReNeuron plans a phase II trial for Retinitis pigmentosa in 1H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top